Emicizumab의 효과 및 안전성에 대한 실사용 근거 생성

• 영문명: Generation of Real-World Evidence on Effectiveness and Safety of Emicizumab: A Systematic Literature Review
• 발행기관: 한국사회약학회 (구.한국보건사회약료경영학회)
• 저자명: 장예원 이한길
• 간행물 정보: 『한국보건사회약료경영학회지』제11권 제2호, 71~81쪽, 전체 11쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2023.11.30

영문 초록

Backgrounds: Emicizumab, a bispecific monoclonal antibody approved by the Food and Drug Administration in 2017 for the treatment of hemophilia, has seen growing usage in South Korea. However, a systematic review of its effectiveness and safety in real-world settings is lacking. Methods: We performed a systematic review following the Preferred Reporting Items for Systematic reviews and Meta-Analyses guideline, searching the PubMed and Cochrane Library databases. Two researchers independently searched and reviewed the literature in two stages, applying predefined inclusion/exclusion criteria and extracting key information from the selected studies. We assessed the quality of studies with the Risk of Bias Assessment tool for Non-randomized Studies (RoBANS). We evaluated emicizumab’s effectiveness and safety using the annual bleeding rate (ABR) and serious adverse events (SAEs) like thrombotic events. Results: Out of 491 relevant studies, 28 studies (1,359 patients) conducted in 14 countries from 2015 to 2022 were included. Among the 17 studies reporting pre- and post-emicizumab ABR changes, 16 demonstrated a decline in ABR, with five indicating a reduction of over 90%. The post-emicizumab ABR varied from 0.09 to 1.4, with 87.1% of cases showing fewer than two bleeds. Among 17 studies (782 patients) examining SAEs, thrombotic events occurred in two studies, affecting four patients (0.51%). The quality assessment by the RoBANS identified a high risk in outcome blinding but low in other domains. Conclusion: The real-world effectiveness and safety of emicizumab are consistent with its clinical trial outcomes, suggesting the need for larger and long-term observational studies in the future.

목차

서 론

연구방법

연구결과

고 찰

결 론

감사의 말씀

참고문헌

키워드

annual bleeding rate emicizumab hemophilia systematic review